» Articles » PMID: 15184909

Analysis of the Activation Status of Akt, NFkappaB, and Stat3 in Human Diffuse Gliomas

Overview
Journal Lab Invest
Specialty Pathology
Date 2004 Jun 9
PMID 15184909
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

Loss of phosphatase and tensin homolog (PTEN) and amplification of the epidermal growth factor receptor (EGFR) gene contribute to the progression of gliomas. As downstream targets of the PTEN and EGFR signaling pathways, Akt, NFkappaB, and signal transducer and activator of transcription-3 (Stat3) have been shown to play important roles in the control of cell proliferation, apoptosis, and oncogenesis. We examined the activation status of Akt, NFkappaB, and Stat3 in 259 diffuse gliomas using tissue microarrays and immunohistochemistry, and evaluated their association with glioma grade. We observed significant positive correlations between the activation status of Akt and NFkappaB and glioma grade. In contrast, only focal immunoreactivity for phospho-Stat3 was observed in < 9% of high-grade gliomas. In addition, we observed a significant correlation between the activation of Akt and NFkappaB. Functional correlation between Akt activation and the activation of NFkappaB was confirmed in U251MG GBM cells in which inhibition of Akt activation either by stable expression of PTEN or by the PI3-kinase inhibitors, wortmannin and LY294002, led to a concomitant decrease in NFkappaB-binding activity. Thus, our results demonstrate that constitutive activation of Akt and NFkappaB, but not Stat3, contributes significantly to the progression of diffuse gliomas, and activation of Akt may lead to NFkappaB activation in high-grade gliomas.

Citing Articles

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.

PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.


A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.

Bhusare N, Kumar M Oncol Res. 2024; 32(5):849-875.

PMID: 38686058 PMC: 11055995. DOI: 10.32604/or.2024.047042.


Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.

Adesoye T, Tripathy D, Hunt K, Keyomarsi K Cancers (Basel). 2024; 16(3).

PMID: 38339245 PMC: 10854592. DOI: 10.3390/cancers16030492.


Combretastatin A-4 suppresses the invasive and metastatic behavior of glioma cells and induces apoptosis in them: in-vitro study.

Karimi Roshan M, Afshari A, Mirzavi F, Mousavi S, Soukhtanloo M Med Oncol. 2023; 40(11):331.

PMID: 37838642 DOI: 10.1007/s12032-023-02197-1.


Advances in the roles of glycyrrhizic acid in cancer therapy.

Zhang Y, Sheng Z, Xiao J, Li Y, Huang J, Jia J Front Pharmacol. 2023; 14:1265172.

PMID: 37649893 PMC: 10463042. DOI: 10.3389/fphar.2023.1265172.